Clinical Trial: QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07113964) titled 'QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)' on Aug. 03.

Brief Summary: This study will evaluate the safety and efficacy of QL1706 and Olaparib in human epidermal growth factor receptor 2 (HER2)-negative unresectable and/or metastatic breast cancer who had received 2-4 line of prior systematic therapy.

Study Start Date: Aug. 30

Study Type: INTERVENTIONAL

Condition: Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

Intervention: DRUG: QL1706 + olaparib

QL1706 is a novel dual immune checkpoint block...